Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype

被引:291
作者
Smith, JS
Alderete, B
Minn, Y
Borell, TJ
Perry, A
Mohapatra, G
Hosek, SM
Kimmel, D
O'Fallon, J
Yates, A
Feuerstein, BG
Burger, PC
Scheithauer, BW
Jenkins, RB
机构
[1] Mayo Clin & Mayo Fdn, Div Lab Genet, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Div Anat Pathol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA
[4] Mayo Clin & Mayo Fdn, Dept Biostat, Rochester, MN 55905 USA
[5] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94115 USA
[6] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94115 USA
[7] Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94115 USA
[8] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA
[9] Ohio State Univ, Div Neuropathol, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
diffuse glioma; tumor suppressor gene; loss of heterozygosity; fluorescence in situ hybridization; comparative genomic hybridization; chromosome; 1; 19;
D O I
10.1038/sj.onc.1202759
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Allelic alterations of chromosomes 1 and 19 are frequent events in human diffuse gliomas and have recently proven to be strong predictors of chemotherapeutic response and prolonged survival in oligodendrogliomas (Cairncross ct al., 1998; Smith et al,, submitted), Using 115 human diffuse gliomas, we localized regions of common allelic loss on chromosomes 1 and 19 and assessed the association of these deletion intervals with glioma histological subtypes. Further, we evaluated the capacity of multiple modalities to detect these alterations, including loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH), The correlation coefficients for detection of 1p and 19q alterations, respectively, between modalities were: 0.98 and 0.87 for LOH and FISH, 0.79 and 0.60 for LOH and CGH, and 0.79 and 0.53 for FISH and CGH, Minimal deletion regions were defined on 19q13.3 (D19S412-D19S596) and 1p (D1S468-D1S1612), Loss of the 1p36 region was found in 18% of astrocytomas (10/55) and in 73% (24/33) of oligodendrogliomas (P < 0.0001), and loss of the 19q13.3 region was found in 38% (21/55) of astrocytomas and 73% (24/33) of oligodendrogliomas (P = 0.0017), Loss of both regions was found in 11% (6/55) of astrocytomas and in 63% (21/33) of oligodendrogliomas (P < 0.0001). All gliomas with LOH on either 1p or 19q demonstrated loss of the corresponding FISH probe, 1p36 or 19q13.3, suggesting not only locations of putative tumor suppressor genes, but also a simple assay for assessment of 1p and 19q alterations as diagnostic and prognostic markers.
引用
收藏
页码:4144 / 4152
页数:9
相关论文
共 47 条
[1]  
[Anonymous], 2003, **DROPPED REF**, DOI DOI 10.1557/MRS2003.194
[2]   AN INTEGRATED METRIC PHYSICAL MAP OF HUMAN-CHROMOSOME-19 [J].
ASHWORTH, LK ;
BATZER, MA ;
BRANDRIFF, B ;
BRANSCOMB, E ;
DEJONG, P ;
GARCIA, E ;
GARNES, JA ;
GORDON, LA ;
LAMERDIN, JE ;
LENNON, G ;
MOHRENWEISER, H ;
OLSEN, AS ;
SLEZAK, T ;
CARRANO, AV .
NATURE GENETICS, 1995, 11 (04) :422-427
[3]  
BAER R, 1993, SEMIN CANCER BIOL, V4, P341
[4]  
BELLO MJ, 1995, INT J CANCER, V64, P207
[5]   MOLECULAR ANALYSIS OF CHROMOSOME-1 ABNORMALITIES IN HUMAN GLIOMAS REVEALS FREQUENT LOSS OF 1P IN OLIGODENDROGLIAL TUMORS [J].
BELLO, MJ ;
VAQUERO, J ;
DECAMPOS, JM ;
KUSAK, ME ;
SARASA, JL ;
SAEZCASTRESANA, J ;
PESTANA, A ;
REY, JA .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (02) :172-175
[6]   CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA [J].
CAIRNCROSS, G ;
MACDONALD, D ;
LUDWIN, S ;
LEE, D ;
CASCINO, T ;
BUCKNER, J ;
FULTON, D ;
DROPCHO, E ;
STEWART, D ;
SCHOLD, C ;
WAINMAN, N ;
EISENHAUER, E .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2013-2021
[7]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[8]   SUCCESSFUL CHEMOTHERAPY FOR RECURRENT MALIGNANT OLIGODENDROGLIOMA [J].
CAIRNCROSS, JG ;
MACDONALD, DR .
ANNALS OF NEUROLOGY, 1988, 23 (04) :360-364
[9]   TP53 GENE-MUTATIONS AND 17P DELETIONS IN HUMAN ASTROCYTOMAS [J].
CHUNG, R ;
WHALEY, J ;
KLEY, N ;
ANDERSON, K ;
LOUIS, DN ;
MENON, A ;
HETTLICH, C ;
FREIMAN, R ;
HEDLEYWHYTE, ET ;
MARTUZA, R ;
JENKINS, R ;
YANDELL, D ;
SEIZINGER, BR .
GENES CHROMOSOMES & CANCER, 1991, 3 (05) :323-331
[10]  
CLIBY W, 1993, CANCER RES, V53, P2393